Normal fasting plasma glucose levels and type 2 diabetes in young men.
暂无分享,去创建一个
D. Pereg | A. Rudich | A. Tirosh | I. Shai | D. Tekes-Manova | E. Israeli | T. Shochat | I. Kochba
[1] J. Bryan,et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis , 2005, Nature Medicine.
[2] J. Després,et al. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. , 2004, Diabetes care.
[3] D. Tanné,et al. Fasting Plasma Glucose and Risk of Incident Ischemic Stroke or Transient Ischemic Attacks: A Prospective Cohort Study , 2004, Stroke.
[4] Wei Chen,et al. Correlates of carotid artery stiffness in young adults: The Bogalusa Heart Study. , 2004, Atherosclerosis.
[5] Y. Miyazaki,et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. , 2004, The Journal of clinical endocrinology and metabolism.
[6] S. Colagiuri,et al. Comment , 2005, Diabetologia.
[7] B. Monia,et al. Role of resistin in diet-induced hepatic insulin resistance. , 2004, The Journal of clinical investigation.
[8] R. Durbin. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance , 2004, Diabetes, obesity & metabolism.
[9] E. Tai,et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. , 2004, Diabetes care.
[10] L. J. Hardies,et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.
[11] M. Laakso,et al. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data , 2004, Diabetologia.
[12] J. Viikari,et al. The 21‐year follow‐up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east–west difference , 2004, Journal of internal medicine.
[13] K. Woo,et al. Deleterious Impact of “High Normal” Glucose Levels and Other Metabolic Syndrome Components on Arterial Endothelial Function and Intima-Media Thickness in Apparently Healthy Chinese Subjects: The CATHAY Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[14] Z. Bloomgarden,et al. Type 2 diabetes in the young: the evolving epidemic. , 2004, Diabetes care.
[15] M. Lazar,et al. Regulation of Fasted Blood Glucose by Resistin , 2004, Science.
[16] D. Schriger,et al. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? , 2004, Diabetes care.
[17] L. Sjöström,et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.
[18] K. Wellen,et al. Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.
[19] Moon-Kyu Lee,et al. The cutoff value of fasting plasma glucose to differentiate frequencies of cardiovascular risk factors in a Korean population. , 2003, Diabetes care.
[20] S. Genuth. Lowering the criterion for impaired fasting glucose is in order. , 2003, Diabetes care.
[21] J. Shaw,et al. Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.
[22] A. D. Diez Roux,et al. Neighborhood characteristics and components of the insulin resistance syndrome in young adults: the coronary artery risk development in young adults (CARDIA) study. , 2002, Diabetes care.
[23] J. Shaw,et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[24] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[25] S. Haffner,et al. Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.
[26] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[27] P. Greenland,et al. Risk Factors for Coronary Heart Disease in Men 18 to 39 Years of Age , 2001, Annals of Internal Medicine.
[28] R. Hanson,et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. , 2000, Diabetes care.
[29] Y. Friedlander,et al. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. , 2000, Australian and New Zealand journal of medicine.
[30] J. Shaw,et al. Impaired fasting glucose: how low should it go? , 2000, Diabetes care.
[31] A. Dyer,et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.
[32] G. Boden. Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.
[33] L. Franco,et al. The ROC Curve in the Evaluation of Fasting Capillary Blood Glucose as a Screening Test for Diabetes and IGT , 1994, Diabetes Care.
[34] R G Shulman,et al. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. , 1991, Science.